V I Avramis - JoVE Visualize

Showing results (31-40 of 43) with videos related to

Pageof 5

Sort By:

Cancer Chemotherapy and Pharmacology|January 1, 1989

Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemiaV I Avramis, R A Mecum, J Nyce, et al.

Cancer Chemotherapy and Pharmacology|September 20, 2001

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 proteinC H Fu, S Martin-Aragon, K I Weinberg, et al.

Anticancer Research|August 15, 1998

Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cellsV I Avramis, P Nandy, R Kwock, et al.

Cancer Research|December 15, 1987

Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemiaV I Avramis, R Biener, M Krailo, et al.

British Journal of Haematology|February 15, 2002

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation systemB K Albertsen, H Schrøder, J Ingerslev, et al.

Anticancer Research|April 19, 2000

Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugsS Martin-Aragon, S K Mukherjee, B J Taylor, et al.

Cancer Research|January 1, 1989

Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drugV I Avramis, K I Weinberg, J K Sato, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantationJ G Villablanca, A A Khan, V I Avramis, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996

Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinosideY Messinger, Y Yanishevski, V I Avramis, et al.

Cancer Research|November 15, 1990

Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patientsV I Avramis, J Champagne, J Sato, et al.

Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:

Pageof 5

Cancer Chemotherapy and Pharmacology|January 1, 1989

Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemiaV I Avramis, R A Mecum, J Nyce, et al.

Cancer Chemotherapy and Pharmacology|September 20, 2001

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 proteinC H Fu, S Martin-Aragon, K I Weinberg, et al.

Anticancer Research|August 15, 1998

Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cellsV I Avramis, P Nandy, R Kwock, et al.

Cancer Research|December 15, 1987

Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemiaV I Avramis, R Biener, M Krailo, et al.

British Journal of Haematology|February 15, 2002

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation systemB K Albertsen, H Schrøder, J Ingerslev, et al.

Anticancer Research|April 19, 2000

Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugsS Martin-Aragon, S K Mukherjee, B J Taylor, et al.

Cancer Research|January 1, 1989

Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drugV I Avramis, K I Weinberg, J K Sato, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantationJ G Villablanca, A A Khan, V I Avramis, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 1996

Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinosideY Messinger, Y Yanishevski, V I Avramis, et al.

Cancer Research|November 15, 1990

Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patientsV I Avramis, J Champagne, J Sato, et al.

Pageof 5